We designed ImmunePrep™, ChemoPrep™ and ChemoPure™ to be adjunct device strategies that enhance the benefit of therapeutic antibodies and cancer chemotherapies.
Our CompanyThe size of the global market for therapeutic antibodies and cancer chemotherapies in 2022.*
We created Sigyn Therapy™ to address pathogen-associated inflammatory disorders that are not treatable with drug therapies. Candidate treatment indications include endotoxemia, drug-resistant bacterial and viral infections, community-acquired pneumonia and sepsis.
"We create medical technologies with two attributes in mind: they must offer to overcome a clearly-defined therapeutic limitation and if demonstrated to be effective, would provide a strategic competitive advantage within an established industry."
Jim Joyce
Chairman and CEO Inventor
Stay informed and receive company updates straight to your inbox.
